Nanobiotix unit in pact with Sanofi on gene therapy

 

• Nanobiotix subsidiary, Curadigm, submitted a research project involving its Nanoprimer technology which was selected for the Sanofi iTech Awards Program, as a highly promising option to significantly improve gene therapy development
• Following this selection, Curadigm will enter into a one-year agreement with the pharmaceutical company including direct funding and scientific exchanges
• This selection provides an opportunity for Curadigm’s Nanoprimer technology, invented at Nanobiotix, to establish proof of concept as a combination product that could expand the benefits of gene therapy and improve treatment outcomes for patients

https://www.businesswire.com/news/home/20210125005694/en/Nanobiotix-Subsidiary-Curadigm-Secures-New-Collaboration-Agreement-With-Sanofi-Focused-on-Gene-Therapy-Pipeline